MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers

Oncogene

Volumn 29, Issue 35, 2010, Pages 4971-4979

  Imam, J S ^a   Buddavarapu, K ^a   Lee Chang, J S ^a   Ganapathy, S ^a   Camosy, C ^a   Chen, Y ^a   Rao, M K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cancer; microRNA; miR 185; Six1; tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 185; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN SIX1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; HOMEODOMAIN PROTEIN; MIRN185 MICRORNA, HUMAN; SIX1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CHILDHOOD CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOLECULAR MECHANICS; MOUSE; NEPHROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE SIX1; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; ADULT; ANIMAL; CELL CYCLE; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADULT; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MICRORNAS; NEOPLASMS; ONCOGENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77956342464     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.233     Document Type: Article

References (25)

1. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A et al. (2007). Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 67: 3036-3042.
2. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L et al. (2004). The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA 101: 6478-6483.
3. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. (2008). Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res 68: 2204-2213.
4. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361.
5. Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. (1998). Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcino-genesis. Proc Natl Acad Sci USA 95: 12608-12613.
6. Grifone R, Demignon J, Houbron C, Souil E, Niro C, Seller MJ et al. (2005). Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo. Development 132: 2235-2249.
7. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM et al. (2002). Gene expression in Wilms0 tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160: 2181-2190.
8. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK et al. (2003). Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426: 247-254.
9. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA et al. (2009). Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 119: 2663-2677.
10. Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM et al. (2006). Clinicopathological significance of homeoprotein Six1 in hepato-cellular carcinoma. Br J Cancer 95: 1050-1055.
11. Ozaki H, Nakamura K, Funahashi J, Ikeda K, Yamada G, Tokano H et al. (2004). Six1 controls patterning of the mouse otic vesicle. Development 131: 551-562.
12. Radisky DC. (2009). Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest 119: 2528-2531.
13. Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL. (2005). Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res 65: 2668-2675.
14. Repetto G, del Peso A, Zurita JL. (2008). Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3: 1125-1131.
15. Shen C, Gu M, Song C, Miao L, Hu L, Liang D et al. (2008). The tumorigenicity diversification in human embryonic kidney 293 cell line cultured in vitro. Biologicals 36: 263-268.
16. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY et al. (2001). Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61: 4942-4946.
17. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. (2009). The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84: 1-16.
18. Wan F, Miao X, Quraishi I, Kennedy V, Creek KE, Pirisi L. (2008). Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer 123: 32-40.
19. Wang S, El-Deiry WS. (2003a). Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 100: 15095-15100.
20. Wang S, El-Deiry WS. (2003b). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.
21. Wang S, El-Deiry WS. (2004). Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64: 6666-6672.
22. Xu PX, Zheng W, Huang L, Maire P, Laclef C, Silvius D. (2003). Six1 is required for the early organogenesis of mammalian kidney. Development 130: 3085-3094.
23. Yu Y, Davicioni E, Triche TJ, Merlino G. (2006). The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 66: 1982-1989.
24. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. (2004). Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181.
25. Zheng W, Huang L, Wei ZB, Silvius D, Tang B, Xu PX. (2003). The role of Six1 in mammalian auditory system development. Development 130: 3989-4000.